Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish

Topical efinaconazole 10% solution is known to be an efficacious and safe treatment modality for toenail onychomycosis. This study will examine the compatibility of topical efinaconazole and nail polish in patients with distal and lateral subungual onychomycosis (DLSO). It is hypothesized that the treatment of DLSO with efinaconazole 10% solution will not be adversely affected by the application of nail polish.

Inclusion criteria

• Female age 19-70, as 19 is the legal age in Alabama
• DLSO affecting at least 1 great toenail diagnosed with positive potassium hydroxide microscopy and culture of a dermatophyte
• Suitable for application of topical antifungal therapy, in the opinion of the investigator
• Target toenail thickness of 3 mm or less as measured by digital caliper, as thickness greater than 3 mm may allow inclusion of patient with severe onychomycosis, and this was the criteria used in the pivotal trial using topical efinaconazole for onychomycosis
• Women of childbearing potential will be required to use birth control and a negative urine pregnancy test must be documented prior to initiating treatment

Exclusion criteria

• History of immunosuppression or concurrent use of immunosuppressant drugs
• History of uncontrolled diabetes mellitus
• History of psoriasis or any other condition that might interfere with the toenail evaluation
• Three or more dermatophytomas (streaks) on the target nail
• Severe DLSO of the target nail
• Patients who cannot refrain from wearing gel or plastic based polishes that are used in salons and that require curing